Related Experiment Videos
[Inhibition of Bcl-2 expression in HL60 cells by incubation with antisense phosphorothioate oligodeoxynucleotides]
1Union Hospital Affiliated to Fujian Medical University, Fujian Institute of Hematology, Fuzhou, Fujian,350001P. R. China.
Objective:
To observe whether the expression of Bcl-2 mRNA and protein in HL60 cells could be decreased by incubation with antisense phosphorothioate oligodeoxnucleotides (ASPO) at different concentrations (5micromol/L,10micromol/L,and 20micromol/L).
Methods:
The expressions of Bcl-2 protein and mRNA in HL60 cells were individually determined by immunocytochemistry, flow cytometry and RT-PCR.
Results:
In the presence of ASPO, the levels of Bcl-2 mRNA and protein could be decreased. The inhibitory effect appeared in the first 24 hours of incubation and became intense as the concentration increased and the time prolonged,but it abated after 72 hours of incubation. Inhibition was not noted in the presence of sense phosphorothioate oligodeoxynucleotides(SPO).
Conclusion:
The data suggested that ASPO could inhibit the expression of Bcl-2 mRNA and protein in HL60 cells and the inhibitory effect depended on the specific sequences, the concentration and the time of incubation, but it could not last very long.
Insights
Antisense phosphorothioate oligodeoxynucleotides (ASPO) effectively reduced Bcl-2 mRNA and protein expression in HL60 cells. This inhibition was sequence-specific, dose-dependent, and time-limited.
Area of Science:
- Molecular Biology
- Gene Expression Regulation
- Oligonucleotide Therapeutics
Context:
- The Bcl-2 gene plays a crucial role in cell apoptosis and is often overexpressed in various cancers.
- Understanding the regulation of Bcl-2 expression is vital for developing targeted cancer therapies.
- Antisense oligonucleotides offer a promising approach for sequence-specific gene silencing.
Purpose:
- To investigate the efficacy of antisense phosphorothioate oligodeoxynucleotides (ASPO) in downregulating Bcl-2 mRNA and protein expression in HL60 cells.
- To determine the dose-dependent and time-dependent effects of ASPO on Bcl-2 expression.
- To confirm the specificity of ASPO by comparing its effects with sense phosphorothioate oligodeoxynucleotides (SPO).
Summary:
- ASPO treatment led to a significant decrease in both Bcl-2 mRNA and protein levels in HL60 cells.
- The inhibitory effect was observed within 24 hours, intensified with increasing ASPO concentration and incubation time, but diminished after 72 hours.
- No inhibition of Bcl-2 expression was observed when cells were treated with SPO, indicating sequence specificity.
Impact:
- These findings demonstrate that ASPO can effectively inhibit Bcl-2 expression in a specific and time-dependent manner.
- ASPO represents a potential therapeutic strategy for conditions characterized by Bcl-2 overexpression, such as certain hematological malignancies.
- Further research into optimizing ASPO delivery and duration could enhance its clinical applicability in cancer treatment.